Monday, August 24, 2020 7:47:45 AM
This is where our consensus seems to be as well, ignore the noise
"I see exactly why Trump held this announcement as well. Word was beginning to spread that Remdesivir has not been helping patients.
There must always be a solution in place even if the solution is not a true one. Hence Remdesivir was swapped out for Plasma. The logic behind him mentioning plasma is that to the layman American public who have no idea how pharma or therapeutics work will think the government has a back up plan. And the benefit of this announcement to the government is the 'plasma' solution has no direct ties to any pharmaceutical company. Hence Gilead is out and no other Pharma is currently in. There will be a secret bidding war amongst Pharma to partner up with NeuroRx and I believe this is being sorted out behind the scenes as we speak. You gotta read between the lines to understand. A deeper game is being played here and alot of money is up for grabs."
CAP structure is important to pay attention to, almost strategic to avoid HTO IMO. The BOD and major stake holders have years worth of acquisition exp. Controlling can be easily be obtained via outstanding warrants.
Best,
JB
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
